Ashvattha Therapeutics, Inc
February 27, 2024
Ophthalmology
Ashvattha is a clinical stage company with a transformative nanomedicine technology exclusively licensed from Johns Hopkins University. The nanomedicine, hydroxyl dendrimers (HDs), precisely targets reactive inflammatory cells anywhere in the body. HD therapeutics (HDTs) are a new drug class that targets diseased tissue and are renally excreted intact in humans without observed toxicity. We have clinical programs in ophthalmology, neurology, and inflammation:
1) Phase 2 chronic dosing study of subcutaneous, anti-angiogenic D-4517.2 in wet AMD and DME patients is ongoing. Results expected 1H24.
2) Phase 1/2 study to image neuroinflammation in ALS, MS, PD and AD patients with 18F-OP-801 is ongoing. Results expected 1H24. Imaging results to support HDT development program.
)
){kind=logo}
)
){kind=logo}
){kind=logo}